These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15184261)

  • 1. Missense mutations in the BRCT domain of BRCA-1 from high-risk women frequently perturb strongly hydrophobic amino acids conserved among mammals.
    Figge MA; Blankenship L
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):1037-41. PubMed ID: 15184261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
    Pavlicek A; Noskov VN; Kouprina N; Barrett JC; Jurka J; Larionov V
    Hum Mol Genet; 2004 Nov; 13(22):2737-51. PubMed ID: 15385441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
    Mirkovic N; Marti-Renom MA; Weber BL; Sali A; Monteiro AN
    Cancer Res; 2004 Jun; 64(11):3790-7. PubMed ID: 15172985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
    Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
    Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
    Magnard C; Bachelier R; Vincent A; Jaquinod M; Kieffer S; Lenoir GM; Venezia ND
    Oncogene; 2002 Oct; 21(44):6729-39. PubMed ID: 12360400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants.
    Di Cecco L; Melissari E; Mariotti V; Iofrida C; Galli A; Guidugli L; Lombardi G; Caligo MA; Iacopetti P; Pellegrini S
    Eur J Cancer; 2009 Aug; 45(12):2187-96. PubMed ID: 19493677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1.
    Williams RS; Green R; Glover JN
    Nat Struct Biol; 2001 Oct; 8(10):838-42. PubMed ID: 11573086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes.
    Ramirez CJ; Fleming MA; Potter JD; Ostrander GK; Ostrander EA
    Oncogene; 2004 Mar; 23(9):1780-8. PubMed ID: 15001988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
    Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
    Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BRCA 1 and BRCA 2 gens in breast cancer].
    Habibović S; Hrgović Z
    Lijec Vjesn; 1998; 120(10-11):342-8. PubMed ID: 19658353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
    Ostrow KL; McGuire V; Whittemore AS; DiCioccio RA
    Cancer Genet Cytogenet; 2004 Sep; 153(2):177-80. PubMed ID: 15350310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
    Drikos I; Nounesis G; Vorgias CE
    Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study.
    Gough CA; Gojobori T; Imanishi T
    Proteins; 2007 Jan; 66(1):69-86. PubMed ID: 17063491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
    Williams RS; Lee MS; Hau DD; Glover JN
    Nat Struct Mol Biol; 2004 Jun; 11(6):519-25. PubMed ID: 15133503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.